AstraZeneca’s blood cancer drug Calquence improves PFS in phase III Ascend trial

This article was originally published here

The trial results demonstrated a statistically-significant and clinically-meaningful improvement in progression-free survival (PFS) with Calquence monotherapy compared against a combination regimen of rituximab plus physician’s choice of idelalisib

The post AstraZeneca’s blood cancer drug Calquence improves PFS in phase III Ascend trial appeared first on Pharmaceutical Business review.

0 replies

Leave a Reply

Want to join the discussion?
Feel free to contribute!

Leave a Reply